Trade

with

Vivus
(NASDAQ: VVUS)
AdChoices
3.40
+0.08
+2.41%
After Hours :
3.35
-0.05
-1.47%

Open

3.38

Previous Close

3.32

Volume (Avg)

927.52k (2.14M)

Day's Range

3.32-3.45

52Wk Range

3.13-10.29

Market Cap.

351.76M

Dividend Rate ( Yield )

-

Beta

1.22

Shares Outstanding

103.46M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Sell
    • Revenue

    • 81.08M

    • Net Income

    • -174.46M

    • Market Cap.

    • 351.76M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -82.10

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.22

    • Forward P/E

    • -2.91

    • Price/Sales

    • 2.68

    • Price/Book Value

    • 2.96

    • Price/Cash flow

    • -8.30

      • EBITDA

      • -153.64M

      • Return on Capital %

      • -25.79

      • Return on Equity %

      • -70.24

      • Return on Assets %

      • -25.79

      • Book Value/Share

      • 1.15

      • Shares Outstanding

      • 103.46M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Sell
        • 1 Year Price Target

        • 4.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.17

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 295.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -4.53

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 84.27

            • 82.75

            • Pre-Tax Margin

            • -82.51

            • 39.38

            • Net Profit Margin

            • -82.10

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 1.83

              • 0.76

              • Current Ratio

              • 7.47

              • 2.92

              • Quick Ratio

              • 6.41

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 3.37

              • 2.21

              • Book Value/Share

              • 1.15

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.33

                • 243.90

                • P/E Ratio 5-Year High

                • -29.92

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.00

                • 124.82

                • Price/Sales Ratio

                • 2.74

                • 9.29

                • Price/Book Value

                • 3.02

                • 8.39

                • Price/Cash Flow Ratio

                • -8.30

                • 49.75

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -70.24

                        (-55.80)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -25.79

                        (-41.70)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -29.37

                        (-45.80)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 0.52

                      • 1.48

                      • Asset Turnover

                      • 0.31

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -154.61M
                      Operating Margin
                      -190.69
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -8.30
                      Ownership

                      Institutional Ownership

                      70.69%

                      Top 10 Institutions

                      50.62%

                      Mutual Fund Ownership

                      16.63%

                      Float

                      94.06%

                      5% / Insider Ownership

                      1.32%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • SPDR® S&P Pharmaceuticals ETF

                      •  

                        3,720,355

                      • 0.00

                      • 3.09

                      • Vanguard Small Cap Index

                      •  

                        1,533,456

                      • 0.21

                      • 1.48

                      • iShares US Pharmaceuticals

                      •  

                        1,464,640

                      • 0.00

                      • 1.22

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,407,028

                      • 0.14

                      • 1.36

                      • iShares Russell 2000 (AU)

                      •  

                        1,353,324

                      • -1.81

                      • 1.13

                      • iShares Nasdaq Biotechnology

                      •  

                        1,344,792

                      • -0.24

                      • 1.12

                      • Vanguard Small Cap Growth Index Fund

                      •  

                        1,030,886

                      • -2.05

                      • 1.00

                      • Vanguard Extended Market Index Fund

                      •  

                        978,191

                      • 0.44

                      • 0.95

                      • iShares Russell 2000 Growth

                      •  

                        632,387

                      • -1.58

                      • 0.53

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        380,623

                      • 0.00

                      • 0.37

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • First Manhattan Company

                      •  

                        9,243,653

                      • -1.72%

                      • 8.94

                      • State Street Corp

                      •  

                        7,478,771

                      • +8.55%

                      • 7.23

                      • Vanguard Group, Inc.

                      •  

                        5,591,029

                      • +0.08%

                      • 5.41

                      • Tahithromos, L.l.c.

                      •  

                        4,924,550

                      • +14.59%

                      • 4.76

                      • BlackRock Fund Advisors

                      •  

                        4,560,193

                      • +16.54%

                      • 4.41

                      • Credit Suisse First Boston (CSFB)

                      •  

                        4,510,991

                      • +6.26%

                      • 4.36

                      • Meditor Capital Management Limited

                      •  

                        2,965,616

                      • -6.70%

                      • 2.87

                      • Sarissa Capital Management LP

                      •  

                        2,573,943

                      • 0.00%

                      • 2.49

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Value

                      VIVUS was incorporated in 1991 as a California corporation and reincorporated in 1996 as a Delaware corporation. The Company is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for ...morelarge underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes. Its FDA- approved therapies includes, Qsymia and STENDRA. Its drug Qsymia (phentermine and topiramate extended-release) was approved by the FDA, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (...moredyslipidemia). Its drug STENDRA, or avanafil, is an oral phosphodiesterase type 5, or PDE5, inhibitor that have licensed from Mitsubishi Tanabe Pharma Corporation. STENDRA was approved by the FDA, for the treatment of erectile dysfunction, or ED, in the United States. Outside the United States, the Company sells products principally in the EU. The Company relies on PDI, Inc., or PDI, a third-party contract sales organization, to assist with the hiring of sales representatives and the promotion of Qsymia to physicians. The Company hold various patents and patent applications in the U.S. and abroad targeting obesity and morbidities related to obesity, including sleep apnea and diabetes, and sexual health, among other. The Company’s prescription pharmaceutical products are subject to extensive pre- and post-marketing regulation by the FDA.lessless

                      Key People

                      Mr. Seth H.Z. Fischer

                      CEO/Director/Other Executive Officer

                      Mr. Svai Sanford

                      CFO/Chief Accounting Officer/Controller

                      Guy P. Marsh

                      General Manager/Vice President, Divisional

                      Dr. Wesley W. Day,PhD

                      Vice President, Divisional

                      Herm Rosenman

                      Director

                      • Vivus

                      • 351 East Evelyn Avenue

                      • Mountain View, CA 94041

                      • USA.Map

                      • Phone: +1 650 934-5200

                      • Fax: +1 650 934-5389

                      • vivus.com

                      Incorporated

                      1991

                      Employees

                      98

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: